References
Original article
Richardson, D. L. et al. Phase 1b study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate, in combination with carboplatin and bevacizumab in patients with platinum-sensitive ovarian cancer. Gynecol. Oncol. 185, 186–193 (2024)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Romero, D. Mirvetuximab soravtansine has activity in platinum-sensitive epithelial ovarian cancer. Nat Rev Clin Oncol 21, 402 (2024). https://doi.org/10.1038/s41571-024-00888-w
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-024-00888-w
- Springer Nature Limited